Business
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio's pipeline.
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"text","content":"SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio's pipeline.","length":562,"tagName":"p"},{"type":"image","alt":"HanchorBio Chairman Scott Liu (left) and WuXi Biologics CEO Chris Chen (right) at the signing ceremony of strategic partnership.","displaySize":"","headline":null,"caption":"HanchorBio Chairman Scott Liu (left) and WuXi Biologics CEO Chris Chen (right) at the signing ceremony of strategic partnership.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/f88fd11dec8ed8ba61dbd4f3ce247646"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_b2kn2A52lTe1fpCJQtKUg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f88fd11dec8ed8ba61dbd4f3ce247646","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/2869146/Strategic_Partnership_Between_Hanchorbio_and_WuXi_Biologics.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under the agreement, WuXi Biologics will provide integrated, end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The collaboration is designed to accelerate clinical translation, enhance CMC execution efficiency, and support scalable global development and manufacturing of HanchorBio's innovative fusion protein portfolio derived from its Fc-Based Designer Biologics (FBDB™) platform.","length":526,"tagName":"p"},{"type":"text","content":"This partnership reflects HanchorBio's strategy to advance its platform-derived, multi-asset pipelines with development speed, manufacturing robustness, and capital efficiency from early clinical stages through commercialization. By leveraging WuXi Biologics' proven capabilities i...